A Phase 1 interventional study of BMS-986497 and Azacitidine in Acute Myeloid Leukemia and Myelodysplastic Syndrome, sponsored by Bristol-Myers Squibb. Terminated at 10 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Inability to meet protocol objectives
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb — 1 open to participants now, 4 under way, none of them phase 3. Leukemia, Myeloid, Acute · Bristol-Myers Squibb.
Among the 43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb, this one is the 17th largest by enrollment of the 30 interventional ones that give a count, is the only one that started in 2024, is one of 16 in phase 1, and was the 41st registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →1 of the 43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb is open now, in 1 country. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 12 · Phase 3 2
First in 2006; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 38 across the 30 interventional studies, 151 across the 11 observational. Of the 36 that completed or were terminated, 9 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
1 of the studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06073769Bristol-Myers SquibbA Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia | 2027-07-30 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with Azacitidine and Venetoclax in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986497
Drug: BMS-986497 · Drug: Azacitidine
Drug: BMS-986497 · Drug: Azacitidine · Drug: Venetoclax
Specified dose on specified days
Also known as: ORM-6151
Specified dose on specified days
Specified dose on specified days
Incidence of dose-limiting toxicities (DLTs)
Time frame: Up to 21 days
Incidence of treatment-emergent adverse events (TEAEs)
Time frame: Up to 2 years
Determine the Recommended Phase 2 Dose (RP2D) of BMS-986497 as Monotherapy
Time frame: Up to 2 years
RP2D of BMS-986497 as Combination Therapy
The combination therapy included BMS-986497 and Azacitidine
Time frame: Up to 2 years
RP2D of BMS-986497 as Triple Combination Therapy
The triple combination therapy included BMS-986497, Azacitidine and Venetoclax.
Time frame: Up to 2 years
Maximum concentration (Cmax)
Time frame: Up to 2 years
Time to reach Cmax (Tmax)
Time frame: Up to 2 years
Area under the curve from time 0 to last quantifiable concentration (AUC0-last)
Time frame: Up to 2 years
Overall response rate (ORR)
Time frame: Up to 4 years
Duration of response (DoR)
Time frame: Up to 4 years
Best overall response (BOR)
Time frame: Up to 4 years
Complete remission (CR)
Time frame: Up to 4 years
Complete remission with incomplete hematologic recovery (Cri)
Time frame: Up to 4 years
Complete remission with partial hematologic recovery (CRh) rate
Time frame: Up to 4 years
Event-free survival (EFS)
Time frame: Up to 4 years
Transition rate to allogeneic hematopoietic stem cell transplantation (HSCT)
Time frame: Up to 4 years
Incidence of Anti-drug antibody (ADA) against BMS-986497
Time frame: Up to 2 years
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from May 2024 to primary completion in Aug 2026, 26 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Feb 2027 → Aug 2026 and completion Sep 2030 → Aug 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Inability to meet protocol objectives
Inability to meet protocol objectives
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.